FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy

BACKGROUND: Fifty percent of patients with muscle–invasive bladder cancer (MI-BC) die from their disease and current chemotherapy treatment only marginally increases survival. Novel therapies targeting receptor tyrosine kinases or activated oncogenes may improve outcome. Hence, it is necessary to st...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Kompier, Lucie C., Lurkin, Irene, van der Aa, Madelon N. M., van Rhijn, Bas W. G., van der Kwast, Theo H., Zwarthoff, Ellen C.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Public Library of Science 2010
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2972209/
https://ncbi.nlm.nih.gov/pubmed/21072204
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0013821
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak